Slide 1: Imugene
ASX: IMU IMUGENE 01 November 2021
Slide 2: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment 4. Neither the Company nor any of its directors, officers, employees, advisers, advice. The presentation is not intended to be comprehensive or provide all associated persons or subsidiaries are liable for any
Slide 3: Introduction to Imugene
Introduction to Imugene Imugene is a biotech company headquartered in Australia and publicly traded on the Australian Securities Exchange (ASX:IMU) 2018 Licensed extensive B cell M AY 2 0 21 portfolio and platform from Licensed onCARlytics SEP 2021 OSU and Mayo Clinic from City of Hope Entered the c
Slide 4: Partnership Highlights
Partnership Highlights • Strategic Research Partnership Eureka Therapeutics, Inc. for the Treatment of Solid Tumours • Collaboration will explore the therapeutic potential of a combination of Imugene’s CD19 oncolytic virus onCARlytics in combination with Eureka’s anti-CD19 ARTEMIS® T-cell therapy fo
Slide 5: Developing Safer and More Effective T-cell Therapies for Solid Tumors
Developing Safer and More Effective T-cell Therapies for Solid Tumors Dr. Cheng Liu President and CEO
Slide 6: Leader in Solid Tumor T-cell Therapy
Leader in Solid Tumor T-cell Therapy Headquartered in San Francisco Bay Area Proprietary ARTEMIS® technology empowering T-cells to infiltrate solid tumors Lead clinical assets to treat liver cancer (HCC) in Phase I/II trials Multiple near-term clinical milestones Multiple partnerships/collaborations
Slide 7: Eureka Ranks in Top CAR-T Patent Assignees Worldwide
Eureka Ranks in Top 10 CAR-T Patent Assignees Worldwide 9 (No. 4 Among Industries) Top CAR-T Cell Patent Assignee Worldwide 2020 7
Slide 8: Eureka ARTEMIS Technology Platform
Eureka ARTEMIS® Technology Platform ARTEMIS Superiority to CAR • ARTEMIS T-cell therapy is clinically validated in patients • ARTEMIS vs. CAR-T • Superior efficacy • Enhanced tumor infiltration • Less T cell exhaustion • Reduced Cytokine Release ARTEMIS receptor is primarily localized in microvilli.
Slide 9: Preclinical Data Demonstrates Superior Safety/Efficacy Profile Compared to CAR T
Preclinical Data Demonstrates Superior Safety/Efficacy Profile Compared to CAR T CD19 ARTEMIS® T cells release less CD19 ARTEMIS® T cells shows CRS-related cytokines than CAR-T, including IL-6 matching efficacy in mouse model (Raji) Mock CD19-CAR CD19 ARTEMIS® CAR-T ARTEMIS Xu et al., Cell Discovery
Slide 10: Tumor Infiltration - ARTEMIS vs. CAR-T cells
Tumor Infiltration - ARTEMIS vs. CAR-T cells Mock CAR ARTEMIS Intravenous (IV) T-cell infusion Subcutaneous Tumor Scans of tumor tissue stained with T-cell marker CD3 show ARTEMIS T cells 100 armed with tumor infiltration technology went deeper into the solid tumor CD3+ Cell Percentage (%) than cont
Slide 11: ARTEMIS Construct Validated by Independent Researchers
ARTEMIS Construct Validated by Independent Researchers Published work with Grupp’s team Xu et al. Cell Discovery (2018) 4:62 ARTEMIS vs. CAR-T cells • Potent anti-tumor activity • Better safety profile • Longer durability with less exhausted phenotype Stephan A. Grupp, MD, PhD 10 11 700 4000 Mock *
Slide 12: Eureka Pipeline
Eureka Pipeline PROGRAM (TARGET)/INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PARTNERS ET140203 (AFP) Adult HCC/Liver Cancer (ARYA-1) ET140203 (AFP) Pediatric Liver Cancers (ARYA-2) ECT204 (GPC3) HCC/Liver Cancer (ARYA-3) Undisclosed Target Mesothelioma, Ovarian & Pancreatic Cancers Undisclosed
Slide 13: The CAR T Solid Tumour Challenge & Imugene's Solution
The CAR T Solid Tumour Challenge & Imugene’s Solution NEW CONCEPT Chimeric Antigen Receptor (CAR) T cell therapy has had limited activity in solid tumours, largely due to a lack of selectively and highly expressed surface antigens, such as the blood B cell antigen Utilise OV’s as a delivery vector t
Slide 14: Mechanism of Action: How does it work?
Mechanism of Action: How does it work? onCARlytics makes solid tumours “seen” by CD19 directed CAR T 1 1. OnCARlytics infects tumour cells 4 2. Virus replication and production of CF33-CD19 on the cell surface 2 enabling CD19 CAR T cell targeting 3. Tumour cell lysis leads to viral particle release
Slide 15: onCARlytics delivers CAR Targets to solid tumours
% 37.8% <1% 6.8% 63.8% 11.5%; this version 98.0% 22.2% 37.8% 63.8% 98.0% bioRxiv preprint doi: https://doi.org/10.1101/843052 posted November 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without
Slide 16: Milestones
Milestones Technology Milestone onCARlytics 1st Patient Dosed onCARlytics FDA IND Clearance PD1-Vaxx Combination RP2D Next 12-24 months onCARlytics GLP Toxicology Study VAXINIA 1st Patient Dosed onCARlytics FDA Pre-IND Meeting onCARlytics GMP manufacturing for pre-clinical toxicology & Phase 1 study
Slide 17: Financial Summary
Financial Summary Public Market Overview Share Price Performance (last 3 months) Share Price 1 A$0.485 52 week range 0.052 - 0.515 Market Capitalisation 2 A$2.73B Cash equivalents (30 Sept 21) A$112.2M Enterprise Value A$2.617B Top 5 Shareholders (as at September 2021) Paul Hopper 6.96% HSBC Custody
Slide 18: Imugene Limited
ASX: IMU IMUGENE LIMITED www.imugene.com info@imugene.com